Citius Pharma receives Nasdaq delisting notice for bid price non-compliance

Citius Pharmaceuticals, Inc.

Received Nasdaq letter on May 29, 2025 for failing minimum $1 bid price for 33 consecutive business days.
Not eligible for compliance period due to reverse stock split within prior year.
Plans to appeal by June 5, 2025 to stay suspension; delisting would start June 9 without appeal.
No assurance that Nasdaq will grant relief or that compliance can be regained.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.